Clinical Trial Update: Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma [Phase 1]

View source ↗

Summary

Phase I trial evaluating pharmacokinetics, safety, efficacy and immunogenicity of the ipilimumab biosimilar HLX13 versus YERVOY in first-line treatment of unres…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• HLX13
• Yervoy (ipilimumab)

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Hepatocellular Carcinoma (HCC) | Phase 1 | Status: RECRUITING